Tirzepatide has a shorter half-life of approximately five days compared to semaglutide at seven days
Figure 1 presents a flowchart of the study selection process
[1] [2] Dysgeusia can result from numerous other causes, including dental disease, oral infections, vitamin deficiencies (particularly zinc and vitamin B12), other medications (such as metronidazole, ACE inhibitors, and certain antibiotics), and systemic conditions such as poorly controlled diabetes itself
D.FasehunL.-K
The organization also warns that since its not approved for human clinical use by any global regulatory authority, it may lead to negative health effects including immunogenic reactions (antibodies), peptide impurities, and limited safety data for proposed routes of use
"People with heart disease or high heart disease risk are more likely to remain alive, keep their kidney function, and stay off dialysis if they are treated with semaglutide." So, how does a drug developed to help people with type 2 diabetes and popularised as a weight-loss therapy help slow the progression of kidney disease